CR20210481A - Formulación sólida del modulador de ensamblaje de la cápside - Google Patents

Formulación sólida del modulador de ensamblaje de la cápside

Info

Publication number
CR20210481A
CR20210481A CR20210481A CR20210481A CR20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A
Authority
CR
Costa Rica
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
CR20210481A
Other languages
English (en)
Inventor
Claire Elisabeth Balmain
Oliver Lenz
Abhishek Singh
Dominique Josiane W Verstraete
Joris Jozef Vandenbossche
Michaël Bertil S Anné
Maria Jansens
Jan Snoeys
Dycke Frederic Anne R Van
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CR20210481A publication Critical patent/CR20210481A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.
CR20210481A 2019-03-13 2020-03-13 Formulación sólida del modulador de ensamblaje de la cápside CR20210481A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Publications (1)

Publication Number Publication Date
CR20210481A true CR20210481A (es) 2021-10-25

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210481A CR20210481A (es) 2019-03-13 2020-03-13 Formulación sólida del modulador de ensamblaje de la cápside

Country Status (16)

Country Link
EP (1) EP3937928A1 (es)
JP (1) JP2022524819A (es)
KR (1) KR20210137484A (es)
CN (1) CN113557016A (es)
AU (1) AU2020235442A1 (es)
BR (1) BR112021017525A2 (es)
CA (1) CA3132095A1 (es)
CR (1) CR20210481A (es)
EC (1) ECSP21067052A (es)
IL (1) IL286209A (es)
JO (1) JOP20210250A1 (es)
MA (1) MA55280A (es)
MX (1) MX2021011030A (es)
PE (1) PE20212107A1 (es)
SG (1) SG11202109710QA (es)
WO (1) WO2020183020A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
CA3090125A1 (en) * 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
CA3090125A1 (en) * 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
JOP20210250A1 (ar) 2023-01-30
BR112021017525A2 (pt) 2021-11-23
SG11202109710QA (en) 2021-10-28
CN113557016A (zh) 2021-10-26
AU2020235442A1 (en) 2021-08-12
KR20210137484A (ko) 2021-11-17
PE20212107A1 (es) 2021-11-04
MA55280A (fr) 2022-01-19
IL286209A (en) 2021-10-31
JP2022524819A (ja) 2022-05-10
WO2020183020A1 (en) 2020-09-17
ECSP21067052A (es) 2021-11-18
MX2021011030A (es) 2021-10-13
CA3132095A1 (en) 2020-09-17
EP3937928A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
PH12020551421A1 (en) Capsid assembly modulator dosing regimen
ZA202500439B (en) Therapeutic compounds for hiv virus infection
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
MY191466A (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
GEP20146134B (en) Inhibitors of hepatitis c virus replication
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MX2018005729A (es) Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
MX2021011030A (es) Formulacion solida del modulador de ensamblaje de la capside.
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
MX2019009659A (es) Dosis mejorada de baloxavir marboxil para pacientes pediatricos.
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202192969A1 (ru) Новые оксалилпиперазины, активные против вируса гепатита b (вгв)
EA202191109A1 (ru) Соединения 5-членного гетероарилкарбоксамида для лечения вируса гепатита в
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
PH12015502258A1 (en) Solid oral dosage formulation of hcv inhibitor in the amorphous state